ibutilide / Generic mfg. 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 


«123»
  • ||||||||||  Corvert (ibutilide) / Pfizer
    Trial primary completion date:  Novel Approaches for Minimizing Drug-Induced QT Interval Lengthening (clinicaltrials.gov) -  Jul 1, 2021   
    P4,  N=83, Not yet recruiting, 
    HFpEF is associated with enhanced response to drug-induced QT interval lengthening. Trial primary completion date: Apr 2025 --> Aug 2025
  • ||||||||||  Corvert (ibutilide) / Pfizer
    Trial completion date, Trial initiation date, Trial primary completion date:  Novel Approaches for Minimizing Drug-Induced QT Interval Lengthening (clinicaltrials.gov) -  May 25, 2021   
    P4,  N=83, Not yet recruiting, 
    The sequential low-dose ibutilide test is a simple method for identifying patients with persistent atrial fibrillation in whom pulmonary vein isolation alone is an appropriate treatment strategy. Trial completion date: Jun 2026 --> Aug 2025 | Initiation date: Jan 2021 --> Jul 2021 | Trial primary completion date: Dec 2025 --> Apr 2025
  • ||||||||||  Corvert (ibutilide) / Pfizer
    Clinical, Journal:  All-Optical Electrophysiology Refines Populations of In Silico Human iPSC-CMs for Drug Evaluation. (Pubmed Central) -  May 15, 2021   
    Furthermore, the in silico investigation yielded mechanistic insights; e.g., through simulations, bepridil's more proarrhythmic action in adult cardiomyocytes compared to hiPSC-CMs could be traced to the different expression of ion currents in the two. Therefore, our work 1) supports the utility of all-optical electrophysiology in providing high-content data to refine experimentally calibrated populations of in silico hiPSC-CMs, 2) offers insights into certain limitations when translating results obtained in hiPSC-CMs to humans, and 3) shows the strength of combining high-throughput in vitro and population in silico approaches.
  • ||||||||||  Corvert (ibutilide) / Pfizer
    Review, Journal:  Does the choice of drug in pharmacologic cardioversion correlate with the guidelines? Systematic review. (Pubmed Central) -  Apr 7, 2021   
    Therefore, our work 1) supports the utility of all-optical electrophysiology in providing high-content data to refine experimentally calibrated populations of in silico hiPSC-CMs, 2) offers insights into certain limitations when translating results obtained in hiPSC-CMs to humans, and 3) shows the strength of combining high-throughput in vitro and population in silico approaches. Our systematic analysis revealed substantial non-adherence to AF treatment guidelines.
  • ||||||||||  Corvert (ibutilide) / Pfizer
    Clinical, Journal:  Chemical Cardioversion of Atrial Flutter and Fibrillation in the Pediatric Population with Ibutilide. (Pubmed Central) -  Mar 16, 2021   
    The success rate of chemical cardioversion with Ibutilide was similar in our experience as compared to studies in the adult population and the other lone pediatric study. While adverse events were uncommon, Ibutilide administration warrants close monitoring and fully defining its efficacy warrants further pediatric experience.
  • ||||||||||  Corvert (ibutilide) / Pfizer
    Journal:  Multicatalytic Approach to the Hydroaminomethylation of α-Olefins. (Pubmed Central) -  Sep 17, 2020   
    By adjusting the ratio of CO to H2, we conducted the reaction at one atmosphere of gas with little change in yield. A diverse array of olefins and amines, including hetreroarylamines that do not react under more conventional conditions with a single catalyst, underwent hydroaminomethylation with this new system, and the pharmaceutical ibutilide was prepared in higher yield and under milder conditions than those reported with a single catalyst.
  • ||||||||||  Brinavess (vernakalant) / Merck (MSD), Correvio
    Journal:  Use of Intravenous Vernakalant for Atrial Fibrillation Conversion in the Regular Ward Under Only Bedside Monitoring. (Pubmed Central) -  Aug 20, 2020   
    A diverse array of olefins and amines, including hetreroarylamines that do not react under more conventional conditions with a single catalyst, underwent hydroaminomethylation with this new system, and the pharmaceutical ibutilide was prepared in higher yield and under milder conditions than those reported with a single catalyst. No abstract available
  • ||||||||||  Corvert (ibutilide) / Pfizer
    Journal:  Prevailing Effects of Ibutilide on Fast Delayed Rectifier K Channel. (Pubmed Central) -  Jun 25, 2020   
    With ibutilide, regardless of pulse duration, a relatively constant ratio was estimated, indicative of predominant involvement of I component. The slow I persisted to greater extent even at 100 μM ibutilide revealing a distinguishable selectivity toward the I component.
  • ||||||||||  rosuvastatin / Generic mfg., AstraZeneca
    Journal:  Intracellular mechanism of rosuvastatin-induced decrease in mature hERG protein expression on membrane. (Pubmed Central) -  Mar 20, 2020   
    In conclusion, Rosuvastatin reduced the expression of hERG plasma membrane by two pathways, the first is to disrupt the transport of immature hERG channels to the membrane, and the second is to increase the degradation of mature hERG channels. In addition, Rosuvastatin potently blocked hERG current, delayed cardiac repolarization and thereby prolonged APDs and QTc intervals. Therefore, caution should be taken when rosuvastatin is used in the treatment of hyperlipidemia, especially when combined with drugs that can prolong the QT interval.
  • ||||||||||  Corvert (ibutilide) / Pfizer, Cardilor (amiodarone) / Generic mfg.
    Journal:  Association of hypokalemia with an increased risk for medically treated arrhythmias. (Pubmed Central) -  Feb 25, 2020   
    Serum potassium levels <3.5mEq/L were associated with an increased hazard for treatment with specific antiarrhythmic drugs in a large cohort of patients admitted to both a cardiac as well as medical and surgical intensive care units. Potassium thresholds may be individualized further based on risk of relevant outcomes.
  • ||||||||||  Corvert (ibutilide) / Pfizer
    Enrollment open:  Reducing the Risk of Drug-Induced QT Interval Lengthening in Women (clinicaltrials.gov) -  May 7, 2019   
    P4,  N=40, Recruiting, 
    Potassium thresholds may be individualized further based on risk of relevant outcomes. Not yet recruiting --> Recruiting
  • ||||||||||  Corvert (ibutilide) / Pfizer
    Enrollment change, Trial completion date, Trial termination, Trial primary completion date:  ECGi Ibutilide: Effect of Ibutilide on AF Source Location and Organization (clinicaltrials.gov) -  Aug 22, 2018   
    P=N/A,  N=1, Terminated, 
    N=20 --> 1 | Trial completion date: Dec 2019 --> Jul 2018 | Recruiting --> Terminated | Trial primary completion date: Nov 2019 --> Jul 2018; 1 patient enrolled (consented) but screen failed. Study stopped as unable to enroll.
  • ||||||||||  Corvert (ibutilide) / Pfizer, Brinavess (vernakalant) / Merck (MSD), Correvio
    Trial completion, Trial primary completion date:  Vernakalant Versus Ibutilide In Recent-Onset Atrial Fibrillation (clinicaltrials.gov) -  May 13, 2015   
    P4,  N=101, Completed, 
    Active, not recruiting --> Completed | Trial primary completion date: Dec 2013 --> Jan 2015 Recruiting --> Completed | Trial primary completion date: Mar 2013 --> May 2015